

BRISTOL MYERS SQUIBB CO  
Form 8-K  
December 28, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934**

**Date of Report (Date of earliest event reported): December 21, 2005**

---

**BRISTOL-MYERS SQUIBB COMPANY**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction

of Incorporation)

**1-1136**  
(Commission File Number)

**22-079-0350**  
(IRS Employer

Identification Number)

**345 Park Avenue**

**New York, NY, 10154**

(Address of Principal Executive Office)

Edgar Filing: BRISTOL MYERS SQUIBB CO - Form 8-K

**Registrant's telephone number, including area code: (212) 546-4000**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On December 22, 2005, Bristol-Myers Squibb Company (Registrant) issued a press release announcing that it had reached on December 21, 2005, a mutually acceptable agreement with Merck & Co., Inc. to terminate the collaborative agreement for muraglitazar, the Registrant's investigational oral medicine for the treatment of type 2 diabetes. Under the termination agreement, all the rights and obligations of the parties under the collaborative agreement, including the standstill provisions, shall have no further force or effect, except for certain limited obligations arising out of events that may have occurred prior to the termination date. The terms of the collaborative agreement were disclosed by the Registrant on Form 8-K filed on May 10, 2004. A copy of the press release is attached to this report as Exhibit 99.1.

**Item 9.01 Financial Statement and Exhibits**

**(d) Exhibits**

99.1 Press release, dated December 22, 2005

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 28, 2005

Bristol-Myers Squibb Company

By: /s/ Sandra Leung

\_\_\_\_\_  
Name: Sandra Leung  
Title: Secretary

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release, dated December 22, 2005